Table 2 Percentage of IFNγ+ naïve γδT cells (Mean ± SD) in CML patients treated with TKIs.

From: Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia

 

MMR by 12 mon

DMR by 36 mon

Mean ± SD

P value

Mean ± SD

P value

Imatinib

Yes

3.2 ± 2.4

0.089

5.0 ± 4.3

0.536

No

6.3 ± 4.1

5.8 ± 3.6

Nilotinib

Yes

11.6 ± 7.3

0.334

12.5 ± 7.5

0.015

No

8.6 ± 6.0

6.0 ± 5.1

Dasatinib

Yes

17.2 ± 12.2

0.085

18.6 ± 11.7

0.003

No

8.6 ± 5.7

6.3 ± 5.9

  1. MMR major molecular response, DMR deep molecular response, mon months.
Back to article page